Jacob Asset Management Of New York LLC Neu Base Therapeutics, Inc. Transaction History

Jacob Asset Management Of New York LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.18 - $0.3 $28,336 - $47,227	-157,424 Reduced 33.46%	313,100 $59,000
Q2 2022 Aug 11, 2022	BUY	$0.82 - $1.93 $36,162 - $85,113	44,100 Added 10.34%	470,524 $494,000
Q4 2021 Feb 09, 2022	BUY	$2.6 - $4.18 $49,202 - $79,102	18,924 Added 4.64%	426,424 $1.2 Million
Q3 2021 Nov 12, 2021	BUY	$3.27 - $4.76 $202,740 - $295,120	62,000 Added 17.95%	407,500 $1.47 Million
Q2 2021 Oct 04, 2021	BUY	$4.63 - $7.34 $509,300 - $807,400	110,000 Added 46.71%	345,500 $1.66 Million
Q1 2021 Oct 04, 2021	BUY	$6.92 - $12.36 $913,440 - $1.63 Million	132,000 Added 127.54%	235,500 $1.74 Million
Q4 2020 Oct 04, 2021	BUY	$6.92 - $9.25 $716,220 - $957,375	103,500 New	103,500 $723,000

Ticker NBSE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,258,700
Description
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...

Get notified when there are updates to the investment portfolio of Jacob Asset Management Of New York LLC, based on Form 13F filings with the SEC.

Stay updated on Jacob Asset Management Of New York LLC with notifications on news.